Company Filing History:
Years Active: 1988-1991
Title: Claus Braestrup: Innovator in Neuropharmacology
Introduction
Claus Braestrup is a notable inventor based in Roskilde, Denmark. He has made significant contributions to the field of neuropharmacology, particularly through his innovative patents. With a total of 2 patents, Braestrup's work has had a profound impact on the understanding and treatment of central nervous system disorders.
Latest Patents
Braestrup's latest patents include groundbreaking compounds that enhance GABA-ergic neurotransmission. The first patent focuses on N-(butenyl substituted) azaheterocyclic carboxylic acids, specifically 1-Aminobut-3-en derivatives. These derivatives feature optionally substituted furanyl, thienyl, pyridyl, and/or pyrrolyl in the 4-position, along with 3-carboxypiperidin-1-yl, 3-carboxytetrahydropyrid-1-yl, or 3-carboxymethylpyrrolidin-1-yl in the 1-position. The second patent introduces novel 2,3,4,5-tetrahydro-1H-3-benzazepines, which exhibit interesting central nervous system and cardiovascular effects.
Career Highlights
Throughout his career, Claus Braestrup has worked with prominent companies such as Novo Industri A/S and Novo Nordisk A/S. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in pharmaceutical research and development.
Collaborations
Braestrup has collaborated with esteemed colleagues, including Peter H. Andersen and Poul Borrevang. These partnerships have fostered a collaborative environment that has led to significant advancements in their respective fields.
Conclusion
Claus Braestrup's contributions to neuropharmacology through his patents and collaborations highlight his role as an influential inventor. His work continues to inspire advancements in the treatment of central nervous system disorders.